RYTM Profile
Rhythm Pharmaceuticals Inc. (RYTM) is a biopharmaceutical company that is focused on developing and commercializing therapies for the treatment of rare genetic disorders of obesity. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
Rhythm's lead product candidate is setmelanotide, which is being developed as a treatment for genetic disorders of obesity such as pro-opiomelanocortin (POMC) deficiency obesity, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl Syndrome (BBS). These disorders are caused by mutations in genes that play a role in regulating appetite and energy expenditure, resulting in severe obesity from a young age.
Setmelanotide is a first-in-class melanocortin-4 receptor (MC4R) agonist that has shown promising results in clinical trials. In clinical studies, setmelanotide has demonstrated significant weight loss in patients with POMC and LEPR deficiency obesity, as well as improvement in hyperphagia (excessive appetite) and other metabolic parameters.
In addition to setmelanotide, Rhythm is also developing other product candidates that target MC4R and other key regulators of energy metabolism. These include RM-853, which is being developed for Prader-Willi Syndrome (PWS), and RM-131, which is being developed for diabetic gastroparesis.
Rhythm has partnerships with Ipsen and Takeda to develop and commercialize setmelanotide globally. The company also has a strong intellectual property portfolio, with a number of issued and pending patents covering its product candidates and technologies.
Overall, Rhythm Pharmaceuticals is a biopharmaceutical company with a focus on developing innovative therapies for rare genetic disorders of obesity. With its lead product candidate setmelanotide showing promising results in clinical trials, and a number of other product candidates in development, Rhythm has the potential to address significant unmet medical needs in this area.
|
